REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies
Diab, A, Marcondes, M, Tagliaferri, M A, Hoch, U, Zhang, J, Rubas, W, Kivimae, S, Zalevsky, J, Conley, A P, Borazanci, E, D'Angelo, S P
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Inhibition of B Cell Receptor-Mediated B Cell Activation and IgE secretion by Coengagement of Surface IgE and FcγRIIb with Fc-Engineered Antibodies
Szymkowski, D.E, Horton, H.H, Chu, S.Y, Zalevsky, J, Herman, H, Pong, E, Desjarlais, J.R
Published in Journal of allergy and clinical immunology (2010)
Published in Journal of allergy and clinical immunology (2010)
Get full text
Journal Article
LBA68 Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)
Tannir, N., Formiga, M.N., Agarwal, N., Pal, S.K., Cho, D., George, D.J., Hong, W., Tang, L., Qureshi, A., Tagliaferri, M.A., Zalevsky, J., Penkov, K.D.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
THU0054 NKTR-358, A NOVEL IL-2 CONJUGATE, STIMULATES HIGH LEVELS OF REGULATORY T CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Siddhanti, S., Fanton, C., Dixit, N., Lu, L., Chindalore, V., Levin, R., Diab, I., Furie, R., Zalevsky, J., Kotzin, B.
Published in Annals of the rheumatic diseases (01.06.2020)
Published in Annals of the rheumatic diseases (01.06.2020)
Get full text
Journal Article
1026TiP A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors
Altan, M., Patnaik, A., Barve, M.A., Dunn, L., Cobb, P.W., Rosenberg, A., Sharma, S., Sukari, A., Lee, Z., Marcondes, M.Q., Zalevsky, J., Tagliaferri, M.A., Kotzin, B., Sacco, A.G.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
83P Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10
Siefker-Radtke, A.O., Hoch, U., Loriot, Y., Balar, A.V., Bilen, M.A., Tannir, N.M., Cho, D.C., Choudhury, A., Chien, D., Yu, D., Currie, S.L., Novotny, J., Santiago, L., Tagliaferri, M.A., Zalevsky, J., Huddart, R.A.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC
Felip, E., Spigel, D.R., Juan Vidal, O.J., Beck, J.T., Aguado de la Rosa, C., Johnson, D.H., Spath-Schwalbe, E., Reinacher-Schick, A., Rodriguez Abreu, D., Altan, M., Reinmuth, N., Edelman, M.J., Reck, M., Zhao, Q., Banerjee, S., Chaudhry, S., Chien, D., Tagliaferri, M.A., Zalevsky, J., Ganti, A.
Published in Annals of oncology (01.12.2021)
Published in Annals of oncology (01.12.2021)
Get full text
Journal Article
446TiPREVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies
Diab, A, Marcondes, M, Tagliaferri, M A, Hoch, U, Zhang, J, Rubas, W, Kivimae, S, Zalevsky, J, Conley, A P, Borazanci, E, D'Angelo, S P
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
Nguyen, M. T. Audrey, Satoh, Hiroaki, Favelyukis, Svetlana, Babendure, Jennie L., Imamura, Takeshi, Sbodio, Juan I., Zalevsky, Jonathan, Dahiyat, Bassil I., Chi, Nai-Wen, Olefsky, Jerrold M.
Published in The Journal of biological chemistry (21.10.2005)
Published in The Journal of biological chemistry (21.10.2005)
Get full text
Journal Article
Combining complementary mechanisms of immune activation: NKTR-214, a biased IL-2 pathway agonist and immune checkpoint antagonists
Charych, D.H., Kuo, P., Addepalli, M., Dixit, V., Pena, R., Rubas, W., Hoch, U., Langowski, J., Doberstein, S.K., Zalevsky, J.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
Diab, A., Hurwitz, M.E., Tannir, N., Bernatchez, C., Haymaker, C., Bentebibel, S.E., Curti, B.D., Wong, M.K.K., Gergel, I., Tagliaferri, M., Zalevsky, J., Hoch, U., Aung, S., Imperiale, M., Cho, D., Tykodi, S.S., Puzanov, I., Kluger, H., Hwu, P., Sznol, M.
Published in Annals of oncology (01.09.2017)
Published in Annals of oncology (01.09.2017)
Get full text
Journal Article
P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
Papadimitrakopoulou, V., Tannir, N., Bernatchez, C., Haymaker, C., Bentebibel, S., Curti, B., Wong, M., Gergel, I., Tagliaferri, M., Zalevsky, J., Hoch, U., Aung, S., Imperiale, M., Cho, D., Tykodi, S., Puzanov, I., Kluger, H., Hurwitz, M., Hwu, P., Sznol, M., Diab, A.
Published in Journal of thoracic oncology (01.11.2017)
Published in Journal of thoracic oncology (01.11.2017)
Get full text
Journal Article
Different WASP family proteins stimulate different Arp2/3 complex-dependent actin-nucleating activities
Zalevsky, Jonathan, Lempert, Leah, Kranitz, Heather, Mullins, R.Dyche
Published in Current biology (11.12.2001)
Published in Current biology (11.12.2001)
Get full text
Journal Article
Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy
Blum, K. A., Smith, M., Fung, H., Zalevsky, J., Combs, D., Ramies, D. A., Younes, A.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article
Crossing Over During Caenorhabditis elegans Meiosis Requires a Conserved MutS-Based Pathway That Is Partially Dispensable in Budding Yeast
Zalevsky, Jonathan, MacQueen, Amy J, Duffy, Joseph B, Kemphues, Kenneth J, Villeneuve, Anne M
Published in Genetics (Austin) (01.11.1999)
Published in Genetics (Austin) (01.11.1999)
Get full text
Journal Article
Transgene-mediated cosuppression in the C. elegans germ line
Dernburg, A F, Zalevsky, J, Colaiácovo, M P, Villeneuve, A M
Published in Genes & development (01.07.2000)
Published in Genes & development (01.07.2000)
Get full text
Journal Article
Inhibition of B Cell Receptor-Mediated B Cell Activation and IgE secretion by Coengagement of Surface IgE and Fc[gamma]RIIb with Fc-Engineered Antibodies
Szymkowski, DE, Horton, HH, Chu, SY, Zalevsky, J, Herman, H, Pong, E, Desjarlais, JR
Published in Journal of allergy and clinical immunology (01.02.2010)
Published in Journal of allergy and clinical immunology (01.02.2010)
Get full text
Journal Article